Global rank tests for multiple, possibly censored, outcomes-Reference-Cited by-同舟云学术

Global rank tests for multiple, possibly censored, outcomes

Published:2016-01-26 Issue:3 Volume:72 Page:926-935
ISSN:0006-341X
Container-title:Biometrics
language:en
Short-container-title:Biom

Author:

Ramchandani Ritesh¹,Schoenfeld David A.¹²,Finkelstein Dianne M.¹²

Affiliation:

1. Department of Biostatistics; Harvard T.H. Chan School of Public Health; 677 Huntington Ave Boston, Massachusetts 02115 U.S.A.

2. Department of Biostatistics; Massachusetts General Hospital; 50 Staniford St. Boston, Massachusetts 02114 U.S.A.

Funder

National Institutes of Health

Publisher

Wiley

Subject

Applied Mathematics,General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/biom.12475/fullpdf

Reference27 articles.

1. The combined assessment of function and survival (cafs): A new endpoint for als clinical trials;Berry;Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,2013

2. Generalized pairwise comparisons of prioritized outcomes in the two-sample problem;Buyse;Statistics in Medicine,2010

3. A limited memory algorithm for bound constrained optimization;Byrd;SIAM Journal on Scientific Computing,1995

4. The alsfrs-r: A revised als functional rating scale that incorporates assessments of respiratory function;Cedarbaum;Journal of the Neurological Sciences,1999

5. Trial of celecoxib in amyotrophic lateral sclerosis;Cudkowicz;Annals of Neurology,2006

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis;Therapeutic Innovation & Regulatory Science;2024-04-17

2. Istore: a project on innovative statistical methodologies to improve rare diseases clinical trials in limited populations;Orphanet Journal of Rare Diseases;2024-03-02

3. The Effect of Non-Overlapping Somatic Mutations in BRAF, NRAS, NF1, or CKIT on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma;Cancers;2024-01-30

4. Composite endpoints, including patient reported outcomes, in rare diseases;Orphanet Journal of Rare Diseases;2023-09-01

5. Exact Permutation and Bootstrap Distribution of Generalized Pairwise Comparisons Statistics;Mathematics;2023-03-20